NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00171678
- Locations
- 🇺🇸
Novartis Consumer Health Inc., Parsippany, New Jersey, United States
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00171054
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00171457
- Locations
- 🇺🇸
Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 62
- Registration Number
- NCT00170729
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00171665
- Locations
- 🇺🇸
Montgomery Rheumatology Associates, Montgomery, Alabama, United States
🇺🇸Drug Research & Analysis Corp, Montgomery, Alabama, United States
🇺🇸Arizona Center for Clinical Research, Glendale, Arizona, United States
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 400
- Registration Number
- NCT00171184
- Locations
- 🇺🇸
Scott Department of Urology Baylor College of Medicine, Houston, Texas, United States
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Registration Number
- NCT00170885
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 134
- Registration Number
- NCT00171067
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00171041
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E.Hanover, New Jersey, United States
Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 92
- Registration Number
- NCT00171756
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
© Copyright 2024. All Rights Reserved by MedPath